Screening of Anticancer Drugs as Potential Candidates to Target COVID-19 Disease

14 May 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


The current work was focused on predicting the potential of several anticancer drugs as potential inhibitors of COVID-19 disease. The work was accoplished using molecular docking performed using SwissDock tool. Information about COVID-19 proteins and anticancer drugs from databases like PDB, PubChem and Drugbank has been incorporated appropriately in the manuscript. Data analysis has revealed some highly promising anticancer drugs which can further be critically analyzed through both computational and biological validation methods.
This work was intended to support the urgent need of finding drugs/remedies against COVID-19. The results can be a foundation for other researchers around the world to further validate/test these anticancer agents against the pathogen.


Anticancer drugs
molecular docking
prediction analysis
therapy alternatives


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.